<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03291743</url>
  </required_header>
  <id_info>
    <org_study_id>RTDB-2201</org_study_id>
    <nct_id>NCT03291743</nct_id>
  </id_info>
  <brief_title>The Biologic Onset of Crohn's Disease: A Screening Study in First Degree Relatives</brief_title>
  <official_title>The Biologic Onset of Crohn's Disease: A Screening Study in First Degree Relatives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dario Sorrentino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carilion Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pursuing very early diagnosis is standard of care for several diseases including colon
      cancer, diabetes and liver disease where an early and aggressive diagnostic and therapeutic
      approach has been shown to change their natural history. Crohn's disease [CD] still lags
      since commonly at presentation CD has already run a long course, often responding poorly to
      therapy or requiring surgery. This innovative project proposes a minimally invasive strategy
      - capsule endoscopy-based screening of first degree relatives [FDR's] of CD patients - to
      develop tools to diagnose CD at or near its biologic onset.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Crohn's Disease (CD) is a form of inflammatory bowel disease (IBD) that affects the
      gastrointestinal tract. CD is a chronic, remitting, and relapsing disease that is rarely
      diagnosed at or near its biological onset. In routine clinical practice, CD diagnosed at the
      pre-clinical stage is largely by chance during routine screening procedures. Current evidence
      suggests these earlier diagnoses lead to better treatment outcomes and may even offer clues
      to better understand the disease's etiology and pathogenesis. Consequently, diagnosing CD at
      an early stage may offer several advantages including better response to medical treatment;
      possible avoidance of long term complications and surgery; and long term cost savings.

      In the last several years it has become apparent that Crohn's Disease tends to evolve over
      time from an inflammatory disease to a fibrosing one due to the repeated healing and repair
      cycles. The fibrosing found in CD is similar to that of other diseases that affect organs
      like the liver and pancreas. Extensive fibrosis (build-up of excessive scar tissue) does not
      respond to drug therapy and must be treated with surgery; therefore, surgical intervention
      (e.g., intestinal resection) is a treatment modality common to CD patients largely due to
      this indication. Ideally, Crohn's Disease should be diagnosed before this irreversible damage
      takes place and while the disease is still responsive to medical therapy; however, the
      disease only comes to medical attention in the presence of symptoms most often associated
      with severe bowel damage such as obstructions and strictures. Even still, the presence of
      these symptoms does not always lead to prompt diagnosis. Additionally, this evidence
      indicates that CD has already run a long course before it becomes symptomatic and further
      supports the need for earlier diagnosis.

      An efficient screening strategy for Crohn's Disease has yet to be identified. To date,
      colonoscopy is considered the gold-standard as there are no noninvasive tests that can
      conclusively screen for disease. Screening the general population has been shown to be
      inefficient due to the overall risk of developing the disease so it is crucial to determine
      the populations at the greatest risk. Crohn's Disease has proven to have a strong genetic
      component. Referral center studies published in the last several years have shown that 5-15%
      of patients with CD have a family history of the disease; therefore, family members of CD
      patients may constitute an ideal population for screening. Familial studies have focused
      mostly on first-degree relatives [FDR] and have found that this group is at a higher risk for
      developing the disease than the general population. In addition, a landmark study published
      in 2003 showed that &gt;40% of asymptomatic first-degree relatives of CD patients [CD-FDR] had
      elevated fecal calprotectin—an intestinal inflammation marker that closely reflects disease
      activity in CD patients—with values between those of healthy controls and FDR's with
      diagnosed disease. Additional abnormalities such as, Anti-Saccharomyces Cerevisae Antibodies
      [ASCA] positivity and elevated inflammatory markers—have also been reported in asymptomatic
      first-degree relatives at a greater proportion than the known risk of developing the disease.

      Recently, at another institution, the investigators conducted an ileocolonoscopy-based
      screening study in 38 first-degree relatives of patients with Crohn's Disease. Identified
      first-degree relatives were carefully excluded in the presence of digestive symptoms or a
      medical history that contained possible causes of intestinal inflammation. The healthy
      control group consisted of 10 age and sex-matched individuals who were scheduled for a
      colonoscopy due to unrelated reasons (e.g., colon cancer screening or rectal bleeding) and
      whose results were found to be normal. In both groups, tissue, blood, and stool samples were
      collected. Median values for fecal calprotectin (FC) and histology were significantly greater
      in first-degree relatives when compared to the healthy controls. Additionally, colonoscopy
      identified three different phenotypes within the first-degree relative population: 1) normal,
      or superimposable to controls; 2) minor lesions (aphthae or small superficial erosions), and
      3) typical features of Crohn's Disease. These findings were confirmed with histological
      scoring that resulted in three highly separated clusters.

      That preliminary research supports the idea that screening within this high-risk population
      allows for earlier diagnosis. Validating these results on a larger scale and with less
      invasive methods may lead to the development of a screening strategy that can be implemented
      as part of routine clinical practice. Additionally, more research is needed to further
      characterize the novel phenotype identified as it may hold crucial clues to the pathogenesis
      of the disease.

      This study seeks to detect asymptomatic, first-degree relatives of patients with established
      Crohn's Disease in hopes of catching the disease at or near its biologic onset (pre-clinical
      stage). Screening will be done using the PillCam™ COLON 2 capsule endoscopy system. Capsule
      findings will be reviewed by Dr. Sorrentino and Dr. Nguyen at the central site. These
      findings will then be verified using proven ileocolonoscopy methods. Blood, stool, and tissue
      specimens will be collected for research-related testing and to be stored for further
      research. Healthy-controls will be enrolled for comparison purposes. The goal of this study
      is to validate the preliminary data from our pilot study using a multi-center approach.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2017</start_date>
  <completion_date type="Anticipated">February 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Crohn's Disease in First Degree Relatives by capsule endoscopy screening</measure>
    <time_frame>coincident at screening</time_frame>
    <description>This study will screen asymptomatic, first-degree relatives of patients with established Crohn's Disease to detect the disease at or near its biologic onset.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of capsule endoscopy with ileocolonoscopy; characterization of disease state</measure>
    <time_frame>coincident at screening</time_frame>
    <description>Evaluate the accuracy of capsule endoscopy (CE) in screening for pre-clinical Crohn's Disease by verifying CE findings with ileocolonoscopy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Genetic Predisposition</condition>
  <condition>IBD</condition>
  <arm_group>
    <arm_group_label>First Degree Relative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 112 high risk first-degree relatives will be enrolled in total. Patients with Crohn's Disease will be given information about the study when in clinic for routine care to share with their first degree relatives (FDR). Screening will be done using capsule endoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This study will also enroll 35 healthy controls who will be age and sex matched to the first degree relative (FDR) population. Enrollment will begin after 20-25 FDR's have passed screening and will continue at this interval until all controls have been enrolled. Controls will be initially screened by colonoscopy. If enrolled they will undergo capsule endoscopy as well</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Capsule endoscopy</intervention_name>
    <description>PillCam(TM) COLON 2 capsule endoscopy system</description>
    <arm_group_label>First Degree Relative</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>PillCam(TM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female who are 18-65 years of age

          -  FDR: Has a first degree relative (mother, father, offspring, or full sibling) who has
             been diagnosed with Crohn's Disease Healthy Controls: Normal colonoscopy and histology
             (if applicable) results, and no family history of inflammatory bowel disease (Crohn's
             Disease and Ulcerative Colitis)

          -  Willingness to comply with protocol requirements, timelines, and procedures

          -  Must be able and willing to provide written consent; medical, surgical, and medication
             history; current and concomitant medication use; and any other documents deemed
             relevant by the investigator.

          -  A negative pregnancy test for all female subjects of childbearing potential at the
             time of consent. Subject must also agree to follow medically approved birth control
             measures while enrolled

        Exclusion Criteria:

          -  Suspected or confirmed diagnosis of inflammatory bowel disease or any other
             gastrointestinal disease or condition

          -  Known medical history of clinically significant cardiovascular, hematologic,
             orthopedic, rheumatologic, muscular, neurologic (e.g. dementia, seizure disorder,
             traumatic brain injury), endocrine, ophthalmologic, infectious (e.g. human
             immunodeficiency virus, tuberculosis, hepatitis), immunologic, renal, pulmonary (e.g.
             COPD), dermatologic, reproductive, or psychiatric disorders, conditions, or diseases
             that would present unacceptable risk to study subjects, compromise the acquisition or
             interpretation of study data, or otherwise interfere with the study subject's
             participation

          -  A systolic blood pressure reading ≥ 180 mmHg and/or a diastolic blood pressure reading
             of ≥ 110 mmHg at screening

          -  An oral temperature reading of 100.5º F or greater

          -  Meets any of the following criteria:

               -  Use of systemic non-steroidal anti-inflammatory medication (including low-dose
                  aspirin) within 14 days prior to consent

               -  History of oral corticosteroid use within 30 days prior to consent

               -  Use of IV corticosteroids within 14 days prior to consent

               -  Treatment with IV anti-infectives within 30 days prior to consent

               -  Treatment with oral anti-infectives within 14 days prior to consent

          -  Previous or current history of malignancy (including fully excised cutaneous basal
             cell carcinoma and squamous cell carcinoma)

          -  History of stem cell or fecal transplant

          -  History of clinically significant alcoholism or substance abuse in the last 12 months,
             as defined in the DSM-IV

          -  Currently has an implanted electrical device (e.g., pacemaker)

          -  Screening lab results were found to be exclusionary based on the following
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dario R Sorrentino, MD, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carilion Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dario R Sorrentino, MD, FRACP</last_name>
    <phone>540-224-5170</phone>
    <email>drsorrentino@carilionclinic.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vu Q Nguyen, MD</last_name>
    <phone>540-206-9226</phone>
    <email>vqnguyen@carilionclinic.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Carilion Clinic</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea L Bidanset, MS</last_name>
      <phone>540-224-6751</phone>
      <email>albidanset@carilionclinic.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002 Jul;8(4):244-50.</citation>
    <PMID>12131607</PMID>
  </reference>
  <reference>
    <citation>Sorrentino D, Fogel S, Van den Bogaerde J. Surgery for Crohn's disease and anti-TNF agents: the changing scenario. Expert Rev Gastroenterol Hepatol. 2013 Nov;7(8):689-700. doi: 10.1586/17474124.2013.842895. Review.</citation>
    <PMID>24161133</PMID>
  </reference>
  <reference>
    <citation>Danese S, Fiorino G, Fernandes C, Peyrin-Biroulet L. Catching the therapeutic window of opportunity in early Crohn's disease. Curr Drug Targets. 2014;15(11):1056-63. Review.</citation>
    <PMID>25198784</PMID>
  </reference>
  <reference>
    <citation>Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, González A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, Heyman M, Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S, Crandall W, Hyams J, Huttenhower C, Knight R, Xavier RJ. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014 Mar 12;15(3):382-392. doi: 10.1016/j.chom.2014.02.005.</citation>
    <PMID>24629344</PMID>
  </reference>
  <reference>
    <citation>Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013 Dec;145(6):1464-78.e1-5. doi: 10.1053/j.gastro.2013.10.046. Review.</citation>
    <PMID>24267475</PMID>
  </reference>
  <reference>
    <citation>Cheifetz AS. Management of active Crohn disease. JAMA. 2013 May 22;309(20):2150-8. doi: 10.1001/jama.2013.4466. Review.</citation>
    <PMID>23695484</PMID>
  </reference>
  <reference>
    <citation>D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van De Mierop FJ, Coche JR, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008 Feb 23;371(9613):660-667. doi: 10.1016/S0140-6736(08)60304-9.</citation>
    <PMID>18295023</PMID>
  </reference>
  <reference>
    <citation>Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan;132(1):52-65. Epub 2006 Nov 29.</citation>
    <PMID>17241859</PMID>
  </reference>
  <reference>
    <citation>Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ; PRECiSE 2 Study Investigators. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010 Jul;105(7):1574-82. doi: 10.1038/ajg.2010.78. Epub 2010 Mar 16.</citation>
    <PMID>20234346</PMID>
  </reference>
  <reference>
    <citation>Peyrin-Biroulet L, Bigard MA, Malesci A, Danese S. Step-up and top-down approaches to the treatment of Crohn's disease: early may already be too late. Gastroenterology. 2008 Oct;135(4):1420-2. doi: 10.1053/j.gastro.2008.08.017. Epub 2008 Sep 4.</citation>
    <PMID>18773901</PMID>
  </reference>
  <reference>
    <citation>Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012 Dec;18(12):2225-31. doi: 10.1002/ibd.22925. Epub 2012 Feb 22.</citation>
    <PMID>22359399</PMID>
  </reference>
  <reference>
    <citation>Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, Peyrin-Biroulet L, Michetti P, Rogler G, Vavricka SR; IBD Cohort Study Group. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013 Nov;108(11):1744-53; quiz 1754. doi: 10.1038/ajg.2013.248. Epub 2013 Aug 27.</citation>
    <PMID>23978953</PMID>
  </reference>
  <reference>
    <citation>Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008 Nov;135(5):1493-9. doi: 10.1053/j.gastro.2008.07.069. Epub 2008 Aug 3.</citation>
    <PMID>18848553</PMID>
  </reference>
  <reference>
    <citation>Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005 Apr;128(4):862-9.</citation>
    <PMID>15825070</PMID>
  </reference>
  <reference>
    <citation>Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004 Jan;99(1):91-6.</citation>
    <PMID>14687148</PMID>
  </reference>
  <reference>
    <citation>Leombruno JP, Nguyen GC, Grootendorst P, Juurlink D, Einarson T. Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. Pharmacoepidemiol Drug Saf. 2011 Aug;20(8):838-48. doi: 10.1002/pds.2132. Epub 2011 Jun 17.</citation>
    <PMID>21688345</PMID>
  </reference>
  <reference>
    <citation>Benevento G, Avellini C, Terrosu G, Geraci M, Lodolo I, Sorrentino D. Diagnosis and assessment of Crohn's disease: the present and the future. Expert Rev Gastroenterol Hepatol. 2010 Dec;4(6):757-66. doi: 10.1586/egh.10.70. Review.</citation>
    <PMID>21108595</PMID>
  </reference>
  <reference>
    <citation>Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM; Swiss IBD Cohort Study Group. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis. 2012 Mar;18(3):496-505. doi: 10.1002/ibd.21719. Epub 2011 Apr 20.</citation>
    <PMID>21509908</PMID>
  </reference>
  <reference>
    <citation>Hovde Ø, Moum BA. Epidemiology and clinical course of Crohn's disease: results from observational studies. World J Gastroenterol. 2012 Apr 21;18(15):1723-31. doi: 10.3748/wjg.v18.i15.1723. Review.</citation>
    <PMID>22553396</PMID>
  </reference>
  <reference>
    <citation>Burgmann T, Clara I, Graff L, Walker J, Lix L, Rawsthorne P, McPhail C, Rogala L, Miller N, Bernstein CN. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome? Clin Gastroenterol Hepatol. 2006 May;4(5):614-20. Epub 2006 Apr 17.</citation>
    <PMID>16630762</PMID>
  </reference>
  <reference>
    <citation>Thjodleifsson B, Sigthorsson G, Cariglia N, Reynisdottir I, Gudbjartsson DF, Kristjansson K, Meddings JB, Gudnason V, Wandall JH, Andersen LP, Sherwood R, Kjeld M, Oddsson E, Gudjonsson H, Bjarnason I. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology. 2003 Jun;124(7):1728-37.</citation>
    <PMID>12806605</PMID>
  </reference>
  <reference>
    <citation>Sorrentino D, Avellini C, Geraci M, Dassopoulos T, Zarifi D, Vadalaʼ di Prampero SF, Benevento G. Tissue studies in screened first-degree relatives reveal a distinct Crohn's disease phenotype. Inflamm Bowel Dis. 2014 Jun;20(6):1049-56. doi: 10.1097/MIB.0000000000000051.</citation>
    <PMID>24788221</PMID>
  </reference>
  <reference>
    <citation>Sorrentino D. Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far? Digestion. 2008;77(1):38-47. doi: 10.1159/000117306. Epub 2008 Feb 19. Review.</citation>
    <PMID>18285676</PMID>
  </reference>
  <reference>
    <citation>Mayberry JF, Ballantyne KC, Hardcastle JD, Mangham C, Pye G. Epidemiological study of asymptomatic inflammatory bowel disease: the identification of cases during a screening programme for colorectal cancer. Gut. 1989 Apr;30(4):481-3.</citation>
    <PMID>2785474</PMID>
  </reference>
  <reference>
    <citation>Sorrentino D. Preclinical and Undiagnosed Crohn's Disease: The Submerged Iceberg. Inflamm Bowel Dis. 2016 Feb;22(2):476-86. doi: 10.1097/MIB.0000000000000612. Review.</citation>
    <PMID>26752471</PMID>
  </reference>
  <reference>
    <citation>Harris R, Sawaya GF, Moyer VA, Calonge N. Reconsidering the criteria for evaluating proposed screening programs: reflections from 4 current and former members of the U.S. Preventive services task force. Epidemiol Rev. 2011;33:20-35. doi: 10.1093/epirev/mxr005. Epub 2011 Jun 10.</citation>
    <PMID>21666224</PMID>
  </reference>
  <reference>
    <citation>Geboes K. The strategy for biopsies of the terminal ileum should be evidence based. Am J Gastroenterol. 2007 May;102(5):1090-2.</citation>
    <PMID>17489785</PMID>
  </reference>
  <reference>
    <citation>Fries W, Renda MC, Lo Presti MA, Raso A, Orlando A, Oliva L, Giofré MR, Maggio A, Mattaliano A, Macaluso A, Cottone M. Intestinal permeability and genetic determinants in patients, first-degree relatives, and controls in a high-incidence area of Crohn's disease in Southern Italy. Am J Gastroenterol. 2005 Dec;100(12):2730-6.</citation>
    <PMID>16393227</PMID>
  </reference>
  <reference>
    <citation>Orholm M, Fonager K, Sørensen HT. Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease. Am J Gastroenterol. 1999 Nov;94(11):3236-8.</citation>
    <PMID>10566721</PMID>
  </reference>
  <reference>
    <citation>Ahmad T, Satsangi J, McGovern D, Bunce M, Jewell DP. Review article: the genetics of inflammatory bowel disease. Aliment Pharmacol Ther. 2001 Jun;15(6):731-48. Review.</citation>
    <PMID>11380312</PMID>
  </reference>
  <reference>
    <citation>Pham M, Leach ST, Lemberg DA, Day AS. Subclinical intestinal inflammation in siblings of children with Crohn's disease. Dig Dis Sci. 2010 Dec;55(12):3502-7. doi: 10.1007/s10620-010-1434-8. Epub 2010 Oct 8.</citation>
    <PMID>20931283</PMID>
  </reference>
  <reference>
    <citation>Montalto M, Curigliano V, Santoro L, Armuzzi A, Cammarota G, Covino M, Mentella MC, Ancarani F, Manna R, Gasbarrini A, Gasbarrini G. Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am J Gastroenterol. 2007 Jan;102(1):132-6. Epub 2006 Nov 13.</citation>
    <PMID>17100982</PMID>
  </reference>
  <reference>
    <citation>Tamboli CP, Richard F, Colombel JF. Fecal calprotectin in Crohn's disease: new family ties. Gastroenterology. 2003 Jun;124(7):1972-4.</citation>
    <PMID>12806631</PMID>
  </reference>
  <reference>
    <citation>Söderholm JD, Olaison G, Lindberg E, Hannestad U, Vindels A, Tysk C, Järnerot G, Sjödahl R. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence? Gut. 1999 Jan;44(1):96-100.</citation>
    <PMID>9862833</PMID>
  </reference>
  <reference>
    <citation>Sendid B, Quinton JF, Charrier G, Goulet O, Cortot A, Grandbastien B, Poulain D, Colombel JF. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol. 1998 Aug;93(8):1306-10.</citation>
    <PMID>9707056</PMID>
  </reference>
  <reference>
    <citation>Ananthakrishnan AN. Environmental risk factors for inflammatory bowel diseases: a review. Dig Dis Sci. 2015 Feb;60(2):290-8. doi: 10.1007/s10620-014-3350-9. Epub 2014 Sep 10. Review.</citation>
    <PMID>25204669</PMID>
  </reference>
  <reference>
    <citation>Peeters M, Geypens B, Claus D, Nevens H, Ghoos Y, Verbeke G, Baert F, Vermeire S, Vlietinck R, Rutgeerts P. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology. 1997 Sep;113(3):802-7.</citation>
    <PMID>9287971</PMID>
  </reference>
  <reference>
    <citation>Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005 Sep;54(9):1232-6.</citation>
    <PMID>16099791</PMID>
  </reference>
  <reference>
    <citation>Efrat B, Iris G, Wang H, Eitan S, Yona K. A subgroup of first-degree relatives of Crohn's disease patients shows a profile of inflammatory markers in the blood which is more typical of Crohn's disease patients than of normal individuals. Mediators Inflamm. 2006;2006(2):74785.</citation>
    <PMID>16883067</PMID>
  </reference>
  <reference>
    <citation>Annese V, Andreoli A, Andriulli A, Dinca R, Gionchetti P, Latiano A, Lombardi G, Piepoli A, Poulain D, Sendid B, Colombel JF. Familial expression of anti-Saccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am J Gastroenterol. 2001 Aug;96(8):2407-12.</citation>
    <PMID>11513182</PMID>
  </reference>
  <reference>
    <citation>Elmgreen J, Both H, Binder V. Familial occurrence of complement dysfunction in Crohn's disease: correlation with intestinal symptoms and hypercatabolism of complement. Gut. 1985 Feb;26(2):151-7.</citation>
    <PMID>3967833</PMID>
  </reference>
  <reference>
    <citation>Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, Vandamme P, Vermeire S. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut. 2011 May;60(5):631-7. doi: 10.1136/gut.2010.223263. Epub 2011 Jan 5.</citation>
    <PMID>21209126</PMID>
  </reference>
  <reference>
    <citation>Mei L, Targan SR, Landers CJ, Dutridge D, Ippoliti A, Vasiliauskas EA, Papadakis KA, Fleshner PR, Rotter JI, Yang H. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology. 2006 Apr;130(4):1078-85.</citation>
    <PMID>16618402</PMID>
  </reference>
  <reference>
    <citation>Devlin SM, Yang H, Ippoliti A, Taylor KD, Landers CJ, Su X, Abreu MT, Papadakis KA, Vasiliauskas EA, Melmed GY, Fleshner PR, Mei L, Rotter JI, Targan SR. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology. 2007 Feb;132(2):576-86. Epub 2006 Nov 10.</citation>
    <PMID>17258734</PMID>
  </reference>
  <reference>
    <citation>Folwaczny C, Noehl N, Endres SP, Heldwein W, Loeschke K, Fricke H. Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives. Dig Dis Sci. 1997 Aug;42(8):1593-7.</citation>
    <PMID>9286222</PMID>
  </reference>
  <reference>
    <citation>Folwaczny C, Noehl N, Tschöp K, Endres SP, Heldwein W, Loeschke K, Fricke H. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterology. 1997 Jul;113(1):101-6.</citation>
    <PMID>9207267</PMID>
  </reference>
  <reference>
    <citation>Bjarnason I, Helgason KO, Geirsson AJ, Sigthorsson G, Reynisdottir I, Gudbjartsson D, Einarsdottir AS, Sherwood R, Kristjansson K, Kjartansson O, Thjodleifsson B. Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology. 2003 Dec;125(6):1598-605.</citation>
    <PMID>14724811</PMID>
  </reference>
  <reference>
    <citation>Dorn SD, Abad JF, Panagopoulos G, Korelitz BI. Clinical characteristics of familial versus sporadic Crohn's disease using the Vienna Classification. Inflamm Bowel Dis. 2004 May;10(3):201-6.</citation>
    <PMID>15290912</PMID>
  </reference>
  <reference>
    <citation>D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998 Feb;114(2):262-7.</citation>
    <PMID>9453485</PMID>
  </reference>
  <reference>
    <citation>Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, Present DH, Rutgeerts P, Schölmerich J, Stange EF, Sutherland LR. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002 Feb;122(2):512-30. Review.</citation>
    <PMID>11832465</PMID>
  </reference>
  <reference>
    <citation>Zwas FR, Cirillo NW, el-Serag HB, Eisen RN. Colonic mucosal abnormalities associated with oral sodium phosphate solution. Gastrointest Endosc. 1996 May;43(5):463-6.</citation>
    <PMID>8726758</PMID>
  </reference>
  <reference>
    <citation>Zhulina Y, Hahn-Strömberg V, Shamikh A, Peterson CG, Gustavsson A, Nyhlin N, Wickbom A, Bohr J, Bodin L, Tysk C, Carlson M, Halfvarson J. Subclinical inflammation with increased neutrophil activity in healthy twin siblings reflect environmental influence in the pathogenesis of inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jul;19(8):1725-31. doi: 10.1097/MIB.0b013e318281f2d3.</citation>
    <PMID>23669399</PMID>
  </reference>
  <reference>
    <citation>Krauss E, Agaimy A, Neumann H, Schulz U, Kessler H, Hartmann A, Neurath MF, Raithel M, Mudter J. Characterization of lymphoid follicles with red ring signs as first manifestation of early Crohn's disease by conventional histopathology and confocal laser endomicroscopy. Int J Clin Exp Pathol. 2012;5(5):411-21. Epub 2012 May 23.</citation>
    <PMID>22808293</PMID>
  </reference>
  <reference>
    <citation>Fujimura Y, Kamoi R, Iida M. Pathogenesis of aphthoid ulcers in Crohn's disease: correlative findings by magnifying colonoscopy, electron microscopy, and immunohistochemistry. Gut. 1996 May;38(5):724-32.</citation>
    <PMID>8707119</PMID>
  </reference>
  <reference>
    <citation>Gullberg E, Söderholm JD. Peyer's patches and M cells as potential sites of the inflammatory onset in Crohn's disease. Ann N Y Acad Sci. 2006 Aug;1072:218-32. Review.</citation>
    <PMID>17057202</PMID>
  </reference>
  <reference>
    <citation>Morson BC. The early histological lesion of Crohn's disease. Proc R Soc Med. 1972 Jan;65(1):71-2.</citation>
    <PMID>5015484</PMID>
  </reference>
  <reference>
    <citation>Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011 Jun 15;474(7351):298-306. doi: 10.1038/nature10208. Review.</citation>
    <PMID>21677746</PMID>
  </reference>
  <reference>
    <citation>Zorzi F, Monteleone I, Sarra M, Calabrese E, Marafini I, Cretella M, Sedda S, Biancone L, Pallone F, Monteleone G. Distinct profiles of effector cytokines mark the different phases of Crohn's disease. PLoS One. 2013;8(1):e54562. doi: 10.1371/journal.pone.0054562. Epub 2013 Jan 17.</citation>
    <PMID>23349929</PMID>
  </reference>
  <reference>
    <citation>Hedin CR, McCarthy NE, Louis P, Farquharson FM, McCartney S, Taylor K, Prescott NJ, Murrells T, Stagg AJ, Whelan K, Lindsay JO. Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings. Gut. 2014 Oct;63(10):1578-86. doi: 10.1136/gutjnl-2013-306226. Epub 2014 Jan 7.</citation>
    <PMID>24398881</PMID>
  </reference>
  <reference>
    <citation>Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014 May;146(6):1489-99. doi: 10.1053/j.gastro.2014.02.009. Epub 2014 Feb 19. Review.</citation>
    <PMID>24560869</PMID>
  </reference>
  <reference>
    <citation>Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology. 2010 Dec;139(6):1816-9. doi: 10.1053/j.gastro.2010.10.036. Epub 2010 Oct 26.</citation>
    <PMID>21029802</PMID>
  </reference>
  <reference>
    <citation>Mukherjee PK, Sendid B, Hoarau G, Colombel JF, Poulain D, Ghannoum MA. Mycobiota in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2015 Feb;12(2):77-87. doi: 10.1038/nrgastro.2014.188. Epub 2014 Nov 11. Review.</citation>
    <PMID>25385227</PMID>
  </reference>
  <reference>
    <citation>Moyes DL, Naglik JR. The mycobiome: influencing IBD severity. Cell Host Microbe. 2012 Jun 14;11(6):551-2. doi: 10.1016/j.chom.2012.05.009. Review.</citation>
    <PMID>22704612</PMID>
  </reference>
  <reference>
    <citation>Iliev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, Brown J, Becker CA, Fleshner PR, Dubinsky M, Rotter JI, Wang HL, McGovern DP, Brown GD, Underhill DM. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science. 2012 Jun 8;336(6086):1314-7. doi: 10.1126/science.1221789. Epub 2012 Jun 6.</citation>
    <PMID>22674328</PMID>
  </reference>
  <reference>
    <citation>Standaert-Vitse A, Sendid B, Joossens M, François N, Vandewalle-El Khoury P, Branche J, Van Kruiningen H, Jouault T, Rutgeerts P, Gower-Rousseau C, Libersa C, Neut C, Broly F, Chamaillard M, Vermeire S, Poulain D, Colombel JF. Candida albicans colonization and ASCA in familial Crohn's disease. Am J Gastroenterol. 2009 Jul;104(7):1745-53. doi: 10.1038/ajg.2009.225. Epub 2009 May 26.</citation>
    <PMID>19471251</PMID>
  </reference>
  <reference>
    <citation>Hedin CR, Stagg AJ, Whelan K, Lindsay JO. Family studies in Crohn's disease: new horizons in understanding disease pathogenesis, risk and prevention. Gut. 2012 Feb;61(2):311-8. doi: 10.1136/gut.2011.238568. Epub 2011 May 11. Review.</citation>
    <PMID>21561876</PMID>
  </reference>
  <reference>
    <citation>Sorrentino D, Avellini C, Geraci M, Vadalà S. Pre-clinical Crohn's disease: diagnosis, treatment and six year follow-up. J Crohns Colitis. 2014 Jul;8(7):702-7. doi: 10.1016/j.crohns.2013.12.008. Epub 2014 Jan 8.</citation>
    <PMID>24411923</PMID>
  </reference>
  <reference>
    <citation>Barnes MJ, Powrie F. Regulatory T cells reinforce intestinal homeostasis. Immunity. 2009 Sep 18;31(3):401-11. doi: 10.1016/j.immuni.2009.08.011. Review.</citation>
    <PMID>19766083</PMID>
  </reference>
  <reference>
    <citation>Fantini MC, Rizzo A, Fina D, Caruso R, Sarra M, Stolfi C, Becker C, Macdonald TT, Pallone F, Neurath MF, Monteleone G. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology. 2009 Apr;136(4):1308-16, e1-3. doi: 10.1053/j.gastro.2008.12.053. Epub 2008 Dec 27.</citation>
    <PMID>19192480</PMID>
  </reference>
  <reference>
    <citation>Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011 May;140(6):1756-1767. doi: 10.1053/j.gastro.2011.02.016. Review.</citation>
    <PMID>21530742</PMID>
  </reference>
  <reference>
    <citation>Papp M, Lakatos PL. Serological studies in inflammatory bowel disease: how important are they? Curr Opin Gastroenterol. 2014 Jul;30(4):359-64. doi: 10.1097/MOG.0000000000000076. Review.</citation>
    <PMID>24811052</PMID>
  </reference>
  <reference>
    <citation>van Schaik FD, Oldenburg B, Hart AR, Siersema PD, Lindgren S, Grip O, Teucher B, Kaaks R, Bergmann MM, Boeing H, Carbonnel F, Jantchou P, Boutron-Ruault MC, Tjønneland A, Olsen A, Crowe FL, Peeters PH, van Oijen MG, Bueno-de-Mesquita HB. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut. 2013 May;62(5):683-8. doi: 10.1136/gutjnl-2012-302717. Epub 2012 Jul 26.</citation>
    <PMID>22842615</PMID>
  </reference>
  <reference>
    <citation>Lönnkvist MH, Theodorsson E, Holst M, Ljung T, Hellström PM. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy. Scand J Gastroenterol. 2011 Apr;46(4):420-7. doi: 10.3109/00365521.2010.539253. Epub 2010 Nov 30.</citation>
    <PMID>21114432</PMID>
  </reference>
  <reference>
    <citation>Kopylov U, Rosenfeld G, Bressler B, Seidman E. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014 Apr;20(4):742-56. doi: 10.1097/01.MIB.0000442681.85545.31. Review.</citation>
    <PMID>24562174</PMID>
  </reference>
  <reference>
    <citation>Sorrentino D, Terrosu G, Paviotti A, Geraci M, Avellini C, Zoli G, Fries W, Danese S, Occhipinti P, Croatto T, Zarifi D. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab--a pilot study. Dig Dis Sci. 2012 May;57(5):1341-8. doi: 10.1007/s10620-011-2025-z. Epub 2012 Jan 18.</citation>
    <PMID>22252267</PMID>
  </reference>
  <reference>
    <citation>Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol. 2010 Jul;8(7):591-9.e1; quiz e78-9. doi: 10.1016/j.cgh.2010.01.016. Epub 2010 Feb 4.</citation>
    <PMID>20139033</PMID>
  </reference>
  <reference>
    <citation>Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R; REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. Epub 2006 Dec 3.</citation>
    <PMID>17324398</PMID>
  </reference>
  <reference>
    <citation>Goutorbe F, Goutte M, Minet-Quinard R, Boucher AL, Pereira B, Bommelaer G, Buisson A. Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease. J Crohns Colitis. 2015 Dec;9(12):1113-9. doi: 10.1093/ecco-jcc/jjv150. Epub 2015 Sep 7.</citation>
    <PMID>26351383</PMID>
  </reference>
  <reference>
    <citation>Sipponen T, Kärkkäinen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008 Nov 15;28(10):1221-9. doi: 10.1111/j.1365-2036.2008.03835.x. Epub 2008 Aug 26.</citation>
    <PMID>18752630</PMID>
  </reference>
  <reference>
    <citation>Soubières AA, Poullis A. Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):41-50. doi: 10.4292/wjgpt.v7.i1.41. Review.</citation>
    <PMID>26855811</PMID>
  </reference>
  <reference>
    <citation>Albert JG, Kotsch J, Köstler W, Behl S, Kaltz B, Bokemeyer B, Dollinger MM, Haerting J, Fleig WE. Course of Crohn's disease prior to establishment of the diagnosis. Z Gastroenterol. 2008 Feb;46(2):187-92. doi: 10.1055/s-2007-963524.</citation>
    <PMID>18253897</PMID>
  </reference>
  <reference>
    <citation>Li Y, Ren J, Wang G, Gu G, Wu X, Ren H, Hong Z, Hu D, Wu Q, Li G, Liu S, Anjum N, Li J. Diagnostic delay in Crohn's disease is associated with increased rate of abdominal surgery: A retrospective study in Chinese patients. Dig Liver Dis. 2015 Jul;47(7):544-8. doi: 10.1016/j.dld.2015.03.004. Epub 2015 Mar 14.</citation>
    <PMID>25840874</PMID>
  </reference>
  <reference>
    <citation>Pellino G, Sciaudone G, Selvaggi F, Riegler G. Delayed diagnosis is influenced by the clinical pattern of Crohn's disease and affects treatment outcomes and quality of life in the long term: a cross-sectional study of 361 patients in Southern Italy. Eur J Gastroenterol Hepatol. 2015 Feb;27(2):175-81. doi: 10.1097/MEG.0000000000000244.</citation>
    <PMID>25461228</PMID>
  </reference>
  <reference>
    <citation>Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001 Dec;49(6):777-82.</citation>
    <PMID>11709511</PMID>
  </reference>
  <reference>
    <citation>Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J, Moum B, Lygren I; IBSEN Study Group. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007 Dec;5(12):1430-8.</citation>
    <PMID>18054751</PMID>
  </reference>
  <reference>
    <citation>Kelly JK, Sutherland LR. The chronological sequence in the pathology of Crohn's disease. J Clin Gastroenterol. 1988 Feb;10(1):28-33.</citation>
    <PMID>3356881</PMID>
  </reference>
  <reference>
    <citation>Greenstein AJ, Lachman P, Sachar DB, Springhorn J, Heimann T, Janowitz HD, Aufses AH Jr. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut. 1988 May;29(5):588-92.</citation>
    <PMID>3396946</PMID>
  </reference>
  <reference>
    <citation>Limketkai BN, Bayless TM. Editorial: Can stenosis in ileal Crohn's disease be prevented by current therapy? Am J Gastroenterol. 2013 Nov;108(11):1755-6. doi: 10.1038/ajg.2013.301.</citation>
    <PMID>24192948</PMID>
  </reference>
  <reference>
    <citation>Jacene HA, Ginsburg P, Kwon J, Nguyen GC, Montgomery EA, Bayless TM, Wahl RL. Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. J Nucl Med. 2009 Nov;50(11):1751-9. doi: 10.2967/jnumed.109.065466. Epub 2009 Oct 16.</citation>
    <PMID>19837758</PMID>
  </reference>
  <reference>
    <citation>Cummings SA, Rubin DT. The complexity and challenges of genetic counseling and testing for inflammatory bowel disease. J Genet Couns. 2006 Dec;15(6):465-76. Review.</citation>
    <PMID>17106630</PMID>
  </reference>
  <reference>
    <citation>Liu JZ, Anderson CA. Genetic studies of Crohn's disease: past, present and future. Best Pract Res Clin Gastroenterol. 2014 Jun;28(3):373-86. doi: 10.1016/j.bpg.2014.04.009. Epub 2014 May 6. Review.</citation>
    <PMID>24913378</PMID>
  </reference>
  <reference>
    <citation>Leighton JA, Gralnek IM, Cohen SA, Toth E, Cave DR, Wolf DC, Mullin GE, Ketover SR, Legnani PE, Seidman EG, Crowell MD, Bergwerk AJ, Peled R, Eliakim R. Capsule endoscopy is superior to small-bowel follow-through and equivalent to ileocolonoscopy in suspected Crohn's disease. Clin Gastroenterol Hepatol. 2014 Apr;12(4):609-15. doi: 10.1016/j.cgh.2013.09.028. Epub 2013 Sep 27.</citation>
    <PMID>24075891</PMID>
  </reference>
  <reference>
    <citation>Triester SL, Leighton JA, Leontiadis GI, Gurudu SR, Fleischer DE, Hara AK, Heigh RI, Shiff AD, Sharma VK. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease. Am J Gastroenterol. 2006 May;101(5):954-64.</citation>
    <PMID>16696781</PMID>
  </reference>
  <reference>
    <citation>Jensen MD, Nathan T, Rafaelsen SR, Kjeldsen J. Diagnostic accuracy of capsule endoscopy for small bowel Crohn's disease is superior to that of MR enterography or CT enterography. Clin Gastroenterol Hepatol. 2011 Feb;9(2):124-9. doi: 10.1016/j.cgh.2010.10.019. Epub 2010 Nov 5.</citation>
    <PMID>21056692</PMID>
  </reference>
  <reference>
    <citation>Sipponen T, Haapamäki J, Savilahti E, Alfthan H, Hämäläinen E, Rautiainen H, Koskenpato J, Nuutinen H, Färkkilä M. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol. 2012 Jul;47(7):778-84. doi: 10.3109/00365521.2012.677953. Epub 2012 Apr 23.</citation>
    <PMID>22519419</PMID>
  </reference>
  <reference>
    <citation>Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005 May;128(5):1172-8.</citation>
    <PMID>15887101</PMID>
  </reference>
  <reference>
    <citation>Gralnek IM, Defranchis R, Seidman E, Leighton JA, Legnani P, Lewis BS. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther. 2008 Jan 15;27(2):146-54. Epub 2007 Oct 23.</citation>
    <PMID>17956598</PMID>
  </reference>
  <reference>
    <citation>Biancone L, Calabrese E, Petruzziello C, Capanna A, Zorzi F, Onali S, Condino G, Lolli E, Ciccacci C, Borgiani P, Pallone F. A family study of asymptomatic small bowel Crohn's disease. Dig Liver Dis. 2014 Mar;46(3):276-8. doi: 10.1016/j.dld.2013.11.003. Epub 2013 Dec 17.</citation>
    <PMID>24360029</PMID>
  </reference>
  <reference>
    <citation>Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004 May;126(6):1518-32. Review.</citation>
    <PMID>15168364</PMID>
  </reference>
  <reference>
    <citation>Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology. 1991 Jun;100(6):1638-43.</citation>
    <PMID>2019369</PMID>
  </reference>
  <reference>
    <citation>Noble CL, Arnott ID. What is the risk that a child will develop inflammatory bowel disease if 1 or both parents have IBD? Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S22-3. doi: 10.1002/ibd.20575. Erratum in: Inflamm Bowel Dis. 2009 Sep;15(9):1438-47.</citation>
    <PMID>18816708</PMID>
  </reference>
  <reference>
    <citation>Russell RK, Satsangi J. Does IBD run in families? Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S20-1. doi: 10.1002/ibd.20573. Review. Erratum in: Inflamm Bowel Dis. 2009 Sep;15(9):1438-47.</citation>
    <PMID>18816757</PMID>
  </reference>
  <reference>
    <citation>Probert CS, Brown M. Are there any ethnic groups that are more likely to develop IBD? Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S24-5. doi: 10.1002/ibd.20601. Erratum in: Inflamm Bowel Dis. 2009 Sep;15(9):1438-47.</citation>
    <PMID>18816723</PMID>
  </reference>
  <reference>
    <citation>Yan B, Panaccione R, Sutherland L. I am Jewish: what is my risk of developing Crohn's disease? Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S26-7. doi: 10.1002/ibd.20691. Erratum in: Inflamm Bowel Dis. 2009 Sep;15(9):1438-47.</citation>
    <PMID>18816782</PMID>
  </reference>
  <reference>
    <citation>Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979 Mar;86(2):420-8. Review.</citation>
    <PMID>18839484</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2017</study_first_submitted>
  <study_first_submitted_qc>September 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Carilion Clinic</investigator_affiliation>
    <investigator_full_name>Dario Sorrentino</investigator_full_name>
    <investigator_title>MD, FRACP, Director, Inflammatory Bowel Diseases</investigator_title>
  </responsible_party>
  <keyword>Crohn's</keyword>
  <keyword>Capsule endoscopy</keyword>
  <keyword>IBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

